Twist Bioscience Corp. (TWST)
103.71
-7.91
(-7.09%)
USD |
NASDAQ |
Nov 20, 09:48
Twist Bioscience Cash from Operations (Quarterly) : -0.173M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.173M |
| June 30, 2026 | 1.115M |
| March 31, 2026 | -17.56M |
| December 31, 2025 | -24.81M |
| September 30, 2025 | -11.81M |
| June 30, 2025 | -1.40M |
| March 31, 2025 | -12.99M |
| December 31, 2024 | -21.43M |
| September 30, 2024 | -15.32M |
| June 30, 2024 | -6.378M |
| March 31, 2024 | -19.42M |
| December 31, 2023 | -22.97M |
| September 30, 2023 | -20.70M |
| June 30, 2023 | -23.41M |
| March 31, 2023 | -44.29M |
| December 31, 2022 | -54.07M |
| September 30, 2022 | -1.267M |
| June 30, 2022 | -34.12M |
| March 31, 2022 | -42.34M |
| Date | Value |
|---|---|
| December 31, 2021 | -46.65M |
| September 30, 2021 | -34.80M |
| June 30, 2021 | -27.96M |
| March 31, 2021 | -24.55M |
| December 31, 2020 | -24.93M |
| September 30, 2020 | -25.20M |
| June 30, 2020 | -23.47M |
| March 31, 2020 | -58.67M |
| December 31, 2019 | -34.91M |
| September 30, 2019 | -23.36M |
| June 30, 2019 | -22.08M |
| March 31, 2019 | -20.81M |
| December 31, 2018 | -21.68M |
| September 30, 2018 | -16.70M |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | -11.46M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | -85.43M |
| Beam Therapeutics, Inc. | -110.75M |
| 10X Genomics, Inc. | 15.83M |
| Moderna, Inc. | -1.559B |
| Prime Medicine, Inc. | -36.68M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -20.25M |
| Cash from Financing (Quarterly) | 438.46M |
| Free Cash Flow | -95.96M |
| Free Cash Flow Per Share (Quarterly) | -0.4135 |
| Free Cash Flow to Equity (Quarterly) | -28.38M |
| Free Cash Flow to Firm (Quarterly) | -26.98M |
| Free Cash Flow Yield | -1.36% |